TBnet webinar "Host-directed TB Therapies" on October 30, 2025
- anneoleischeck
- 4 days ago
- 2 min read
Dear Colleagues,
We invite you to join us on 30 October 2025 at 17:00 CET for the newest TBnet webinar with the topic "Host-directed TB Therapies". We look forward to your participation!
Please register for this webinar in advance using the link below:
After registering, you will receive a confirmation email containing information about joining the webinar
Contact information: admin@tbnet.eu
Speakers:
Robert Wallis is an Infectious Disease physician and translational research scientist whose career has spanned academic and pharmaceutical industry positions. He currently holds adjunct appointments as Professor at Case Western Reserve (Cleveland) and Vanderbilt (Nashville) Universities. His research has focused on the development of TB host-directed therapies, antimicrobial drugs, biomarkers, and vaccines. At Pfizer, he chaired the Technical Review Committee responsible for guiding all clinical Infectious Disease research and led the team responsible for the development of sutezolid, an oxazolidinone, for TB. Since 2014, he has served as the Chief Science Officer for the Aurum Institute, a non-profit South African research institute dedicated to improving the health of people around the world living in poverty. As CSO, Prof Wallis is responsible for the development of translational and clinical research programs to advance host-directed and antimicrobial therapies for tuberculosis treatment and prevention.
Cristina Vilaplana is a Specialist in Clinical Microbiology and holds a Master’s in Healthcare Organisation Management. She is currently Head of the Experimental Tuberculosis Unit at the Germans Trias i Pujol Research Institute and Hospital (IGTP–HUGTiP) and she is also affiliated with the Department of Genetics and Microbiology at the Autonomous University of Barcelona (UAB). In addition, she serves as Coordinator of the TB Management Plan for the hospital and its referral area.
Her research focuses on the design and evaluation of new therapeutic strategies against infectious diseases, with over 15 years of experience in both experimental animal models and clinical studies and trials. Additional areas of expertise include the study of biomarkers and tools for monitoring TB disease progression and prognosis, as well as the assessment of health dimensions and quality of life in the context of infectious diseases.
Chair:
Gunar Günther is a pulmonologist, currently working at Inselspital, Hospital of the University of Bern (Switzerland) and Katatura State Hospital / School of Medicine of the University of Namibia (Windhoek, Namibia). Gunar is member of TBnet since 2008 and has a strong interest in capacity building, operational research and clinical TB care in Europe and Africa. He is the vice chair of TBnet since 2023.
Comments